Related references
Note: Only part of the references are listed.CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek et al.
LEUKEMIA (2021)
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients
Fuli Fan et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma
Kirk E. Cahill et al.
LEUKEMIA & LYMPHOMA (2020)
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Seshu Tyagarajan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Jing Pan et al.
LEUKEMIA (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela Maus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
Liora M. Schultz et al.
BLOOD (2020)
CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers
Lingyan Wang et al.
BLOOD (2020)
Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
Jenna Rossoff et al.
BLOOD (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia
Diego Sanchez-Martinez et al.
BLOOD (2019)
Relapsed T Cell ALL: Current Approaches and New Directions
Christine M. McMahon et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Chimeric Antigen Receptors for T-Cell Malignancies
Lauren D. Scherer et al.
FRONTIERS IN ONCOLOGY (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan Grupp et al.
BLOOD (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Mathew L. Cooper et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski et al.
BLOOD (2019)
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Liora M. Schultz et al.
BLOOD (2019)
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Lauren C. Fleischer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype
Saisai Li et al.
HUMAN GENE THERAPY (2018)
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
Wenting Zheng et al.
LEUKEMIA (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia
Jaclyn Rosenthal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial
Fang Liu et al.
BLOOD (2018)
Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy
Rebecca Gardner et al.
BLOOD (2018)
TCR alpha beta/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy
Jane Rasaiyaah et al.
JCI INSIGHT (2018)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
Iulia Diaconu et al.
MOLECULAR THERAPY (2017)
T memory stem cells in health and disease
Luca Gattinoni et al.
NATURE MEDICINE (2017)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M. Maciocia et al.
NATURE MEDICINE (2017)
Gemtuzumab ozogamicin for acute myeloid leukemia
Frederick R. Appelbaum et al.
BLOOD (2017)
Decreased Relapsed Rate and Treatment-Related Mortality Contribute to Improved Outcomes for Pediatric Acute Myeloid Leukemia in Successive Clinical Trials
Thomas B. Alexander et al.
CANCER (2017)
Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies
Liyanage P. Perera et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Frontline treatment of acute myeloid leukemia in adults
Gevorg Tamamyan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
Changes in the survival of older patients with hematologic malignancies in the early 21st century
Dianne Pulte et al.
CANCER (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Nathan Singh et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation
Daniel W. Lee et al.
BLOOD (2016)
How I treat T-cell acute lymphoblastic leukemia in adults
Mark R. Litzow et al.
BLOOD (2015)
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Maksim Mamonkin et al.
BLOOD (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An inducible caspase 9 safety switch for T-cell therapy
KC Straathof et al.
BLOOD (2005)
Share Paper
